Monitoring COVID-19 NAbs dynamics remains dissolved as the lack of analytical strategies deployable in most practice, as stably remaining protein activity seems particularly difficult. We engineer selenium nanoparticles for LFIA that preserves protein activity and enhances stability. NAbs levels decrease with age and over time after infection, and they drop sharply with neurological and hematological diseases according to 1,328 samples. Our work provides a reliable and universally platform for next-generation point-of-care immunity monitoring and vaccine evaluation.

Anti-angiogenic therapies targeting VEGF signaling have limited clinical efficacy due to inevitable resistance. Researchers constructed a pancancer single-cell atlas of 1.24 million cells across 13 cancer types, revealing that pericytes (PCs) and PC-derived PGF/ANGPT2 are more prominent pro-angiogenic regulators than the classical VEGFA-centric model. Tumor-educated MCAM+ immature PCs (imPCs) were identified as the primary source of PGF/ANGPT2, driving alternative angiogenesis and anti-VEGFR resistance. Combining anti-VEGFR with MCAM-targeting antibody-drug conjugates achieved superior tumor control through dual EC/PC inhibition.

This review summarizes recent advances in wearable uric acid sensors, covering electrochemical and optical detection mechanisms, performance-enhancement strategies, device integration, and emerging applications. It highlights progress in sensitivity, selectivity, anti-fouling performance, self-calibration, and user comfort, while identifying persistent challenges in long-term stability, interference resistance, multimodal monitoring, clinical validation, data security, and commercialization. Future directions emphasize intelligent, sustainable, and personalized sensing platforms.

Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with variable responses to radiotherapy. Identifying reliable biomarkers to predict treatment response remains an urgent clinical need. This study investigated secretory leukocyte peptidase inhibitor (SLPI) as a dynamic biomarker for radiotherapy response in ESCC. We found that SLPI expression correlated with treatment outcomes and may serve as a prognostic indicator for ESCC patients undergoing radiotherapy. These findings could help guide personalized treatment decisions and improve outcomes for ESCC patients.

Patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapy face increased risks of infections, including hepatitis B virus (HBV) reactivation. This nationwide real-world study investigated the incidence and risk factors of HBV infection or reactivation and HBV-related liver dysfunction in Chinese IBD patients treated with infliximab. Our findings provide important insights for HBV screening and prophylactic antiviral therapy in this vulnerable population. The study emphasizes the need for careful monitoring and management of HBV status in IBD patients initiating biologic therapy.

The brain and body interact bidirectionally through complex neural, endocrine, immune, and metabolic pathways. Systemic diseases can affect brain structure and function, while brain disorders can influence peripheral organ systems. This review surveys recent neuroimaging studies that reveal disease-specific brain alterations across multiple systemic conditions, including cardiovascular, metabolic, autoimmune, and infectious diseases. We highlight common and distinct patterns of brain involvement and discuss the potential of imaging biomarkers for early diagnosis and therapeutic monitoring. Advanced imaging techniques provide unprecedented insights into brain-body interactions in health and disease.

Muscle and bone, key tissues that maintain the body's structure and function, are closely connected both anatomically and physiologically. Growing evidence suggests that vascular dysfunction serves as a critical link between sarcopenia and osteoporosis. This review summarizes the structural and functional interactions between the musculoskeletal and vascular systems, examines shared mechanisms underlying sarcopenia and osteoporosis, and discusses potential therapeutic strategies targeting vascular health to mitigate both conditions. The crosstalk between muscle-derived and bone-derived factors, mediated by the vascular system, offers new insights for understanding and treating these age-related conditions.

 

Clear cell renal cell carcinoma (ccRCC) is characterized by frequent mutations in genes involved in chromatin remodeling and DNA damage repair. This review examines how essential genetic mutations in ccRCC impair DNA damage repair mechanisms and simultaneously modulate the tumor immune microenvironment. We discuss the interplay between genomic instability and immune response, highlighting how mutations in key genes such as VHL, PBRM1, and BAP1 create therapeutic vulnerabilities. Understanding these relationships may inform novel combination strategies targeting both DNA repair pathways and immune checkpoint mechanisms in ccRCC.

Published in Journal of Bioresources and Bioproducts, the review systematically summarizes recent advancements in multifunctional paper-based smart packaging. It highlights core modification strategies—internal additive incorporation, impregnation, coating, surface functionalization, and layer-by-layer assembly—that transform paper from passive protection into active regulation and intelligent sensing platforms. The authors discuss matrix-specific synergistic systems tailored to fresh produce and high-protein foods, while critically analyzing challenges including the recyclability paradox of high-performance coatings, unpredictable migration safety, and the scalability gap between laboratory innovation and industrial production.

A key challenge in cancer precision oncology is the limited ability of genomic analyses to accurately predict changes in protein expression or function, even though proteins serve as the main targets of numerous modern therapies. Bridging this gap necessitates precise quantification of proteins and their post-translational modifications (PTMs). Recent advances in mass spectrometry (MS)-based proteomics now enable large-scale, quantitative characterization of proteins and PTMs in tumor tissues. To link genomic aberrations to cancer phenotypes, the emerging field of proteogenomics integrates proteomic data, including PTMs, with genomic, epigenomic, and transcriptomic information. This comprehensive approach offers a deeper understanding of cancer biology at multiple levels. This review highlights recent advancements in MS-based proteomics, key discoveries in cancer proteogenomics, and the transformative potential of this field in decoding the complexities of cancer across diverse dimensions.